Related Experiment Video
Updated: May 5, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
17.8K
Targeting the Renin-angiotensin-aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological
J Pawlonka1, B Buchalska2, K Buczma2
1Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland. jan.pawlonka@wum.edu.pl.
Current Treatment Options in Oncology
|October 18, 2024
Summary
The renin-angiotensin-aldosterone system (RAAS) impacts cancer and cardiovascular toxicities (CVTs). RAAS inhibitors may offer protective benefits in cancer therapy and CVT prevention, improving patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Oncology
- Pharmacology
Background:
- The renin-angiotensin-aldosterone system (RAAS) is vital for cardiovascular regulation and a therapeutic target.
- RAAS dysregulation is linked to hypertension, heart failure, and increasingly, cancer biology and associated cardiovascular toxicities (CVTs).
- Modern oncological treatments, including anthracyclines, anti-HER2 therapies, immune checkpoint inhibitors (ICIs), and VEGF inhibitors, significantly improve survival but carry substantial cardiovascular risks.
Purpose of the Study:
- To explore the role of the RAAS in cancer development and treatment-related CVTs.
- To evaluate the potential of RAAS inhibitors (RAASi) as supplementary therapies for cancer treatment.
- To assess the utility of RAASi in preventing or mitigating CVTs associated with oncological therapies.
Main Methods:
- Literature review and synthesis of existing research on RAAS, cancer, and cardiovascular toxicities.
- Analysis of the mechanisms by which RAAS influences tumor growth and cardiovascular health.
- Examination of preclinical and clinical data regarding the use of RAAS inhibitors in oncological settings.
Main Results:
- RAAS plays a complex role in tumor progression, angiogenesis, and metastasis.
- Various cancer therapies induce distinct patterns of CVTs, highlighting the need for targeted cardioprotective strategies.
- Emerging evidence suggests RAAS inhibitors may ameliorate certain CVTs and potentially enhance anti-cancer efficacy.
Conclusions:
- Understanding the intricate relationship between RAAS, cancer, and CVTs is crucial for advancing patient care.
- RAAS inhibitors represent a promising adjunctive therapeutic strategy for both managing cancer and preventing its cardiovascular complications.
- Personalized treatment approaches integrating RAAS modulation could significantly improve oncological treatment outcomes and patient safety.
Related Concept Videos
01:33Hormonal Regulation
30.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
30.4K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:29Hypertension II: Pathophysiology
1.8K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K